251. Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies.
- Author
-
Liu, Qian, Zhang, Jing, Guo, Chenchen, Wang, Mengcheng, Wang, Chenfei, Yan, Yilv, Sun, Liangdong, Wang, Di, Zhang, Lele, Yu, Huansha, Hou, Likun, Wu, Chunyan, Zhu, Yuming, Jiang, Gening, Zhu, Hongwen, Zhou, Yanting, Fang, Shanhua, Zhang, Tengfei, Hu, Liang, and Li, Junqiang
- Subjects
- *
SMALL cell lung cancer , *DNA repair , *PROGNOSIS , *MULTIOMICS , *IMMUNOSUPPRESSION - Abstract
We performed comprehensive proteogenomic characterization of small cell lung cancer (SCLC) using paired tumors and adjacent lung tissues from 112 treatment-naive patients who underwent surgical resection. Integrated multi-omics analysis illustrated cancer biology downstream of genetic aberrations and highlighted oncogenic roles of FAT1 mutation, RB1 deletion, and chromosome 5q loss. Two prognostic biomarkers, HMGB3 and CASP10, were identified. Overexpression of HMGB3 promoted SCLC cell migration via transcriptional regulation of cell junction-related genes. Immune landscape characterization revealed an association between ZFHX3 mutation and high immune infiltration and underscored a potential immunosuppressive role of elevated DNA damage response activity via inhibition of the cGAS-STING pathway. Multi-omics clustering identified four subtypes with subtype-specific therapeutic vulnerabilities. Cell line and patient-derived xenograft-based drug tests validated the specific therapeutic responses predicted by multi-omics subtyping. This study provides a valuable resource as well as insights to better understand SCLC biology and improve clinical practice. [Display omitted] • Integrated multi-omics reveals functional impacts of genomic alteration • HMGB3 promotes cell migration and is a prognostic indicator • ZFHX3 mutation is associated with higher immune response • Four multi-omics subtypes inform precision patient treatment Comprehensive proteogenomic characterization of small cell lung cancer using paired tumor and normal adjacent tissues provides insights into tumorigenesis, potential prognostic biomarkers, and immune landscape; identifies therapeutic strategies for four subtypes; and creates a resource for further research. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF